- Novartis' (NYSE:NVS) fully human mAb, AIN457 (secukinumab), meets its primary and key secondary endpoints in two Phase 3 clinical trials assessing its safety and efficacy as a treatment for the symptoms of ankylosing spondylitis. The company plans to present the data at an upcoming medical congress.
- Secukinumab neutralizes the action of IL-17A, a protein that stimulates inflammation. Several days ago, an FDA Advisory Committee voted unanimously in favor of approval for the mAb for the treatment of moderate-to-severe plaque psoriasis.